作者
Rudragouda Channappanavar, Anthony R Fehr, Jian Zheng, Christine Wohlford-Lenane, Juan E Abrahante, Matthias Mack, Ramakrishna Sompallae, Paul B McCray, David K Meyerholz, Stanley Perlman
发表日期
2019/9/3
期刊
The Journal of clinical investigation
卷号
129
期号
9
页码范围
3625-3639
出版商
American Society for Clinical Investigation
简介
Type 1 IFNs (IFN-I) generally protect mammalian hosts from virus infections, but in some cases, IFN-I is pathogenic. Because IFN-I is protective, it is commonly used to treat virus infections for which no specific approved drug or vaccine is available. The Middle East respiratory syndrome–coronavirus (MERS-CoV) is such an infection, yet little is known about the role of IFN-I in this setting. Here, we show that IFN-I signaling is protective during MERS-CoV infection. Blocking IFN-I signaling resulted in delayed virus clearance, enhanced neutrophil infiltration, and impaired MERS-CoV–specific T cell responses. Notably, IFN-I administration within 1 day after infection (before virus titers peak) protected mice from lethal infection, despite a decrease in IFN-stimulated gene (ISG) and inflammatory cytokine gene expression. In contrast, delayed IFN-β treatment failed to effectively inhibit virus replication; increased infiltration and …
引用总数
学术搜索中的文章